



巴斯德讲坛-资深讲坛系列 Pasteur Colloquium-Senior

Dysbiosis of Gut Microbiome and Alzheimer' Disease and Therapeutic Implication



Dr,Meiyu GENG

*Professor, Principle investigator
Shanghai Institute of Materia Medica, Chinese Academy of Sciences*

Dr. Geng's research is focused on the innovative drug discovery and development to promote conceptual and clinical breakthroughs in disease areas with huge unmet medical needs, such as Alzheimer's disease (AD) and cancer. She has played a leading role in the development of the first-in-class anti-AD treatment GV-971, conditional approved in China in 2019 and got formal approval in 2020 from the US Food and Drug Administration (FDA) for its international multi-center Phase III clinical study in the U.S.. She has also led the development of over ten targeted anticancer therapies, including seven undergoing clinical trials in China. In parallel to anticancer drug discovery, her team is engaged in biomarker discovery to guide personalized cancer therapy and mechanism-based combination therapies. Dr. Geng has published more than 240 research articles in peer-review journals including Cell, Cancer Cell, Cell Res, J Natl Cancer Inst, Nature Commun, Hepatology, Cancer Res etc.


A201, Life Science Research Building

1:30 PM - 3:00 PM

September 14th, 2020

Host: Guangxun Meng

腾讯会议直播间 (Tencent Meeting teleconference room): 106 451 555



**CAS KEY LABORATORY OF MOLECULAR
VIROLOGY & IMMUNOLOGY**
中国科学院分子病毒与免疫重点实验室



中国科学院上海巴斯德研究所
Institut Pasteur of Shanghai
Chinese Academy of Sciences

The Center for Microbes, Development and Health
微生物、发育与健康研究中心